{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:01:27Z","timestamp":1794344487305,"version":"4.9.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013122","name":"Fondazione Oncologia Niguarda Onlus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013122","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open access funding provided by Universit\u00e0 degli Studi di Milano within the CRUI-CARE Agreement"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40265-025-02253-2","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:27:44Z","timestamp":1763382464000},"page":"37-57","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies"],"prefix":"10.1007","volume":"86","author":[{"given":"Caterina","family":"Vaghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Bonazzina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Amatu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bencardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Piscazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Roazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bombelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Marrapese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ghezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Patelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Elez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-0409","authenticated-orcid":false,"given":"Andrea","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"2253_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3322\/CAAC.21772","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A, Siegel RL. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233\u201354. https:\/\/doi.org\/10.3322\/CAAC.21772.","journal-title":"CA Cancer J Clin"},{"key":"2253_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/J.ANNONC.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332. https:\/\/doi.org\/10.1016\/J.ANNONC.2022.10.003.","journal-title":"Ann Oncol"},{"key":"2253_CR3","unstructured":"Colon cancer\u2014guidelines. Detail Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1428. Accessed on 22 May 2025."},{"key":"2253_CR4","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/ANNONC\/MDY100","volume":"29","author":"S Siena","year":"2018","unstructured":"Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29:1108\u201319. https:\/\/doi.org\/10.1093\/ANNONC\/MDY100.","journal-title":"Ann Oncol"},{"key":"2253_CR5","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1093\/ANNONC\/MDY156","volume":"29","author":"RYC Tan","year":"2018","unstructured":"Tan RYC, Camat MD, Ng M, Lim TH, Lim AST, Lim KH, et al. HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients. Ann Oncol. 2018;29:1598\u2013603. https:\/\/doi.org\/10.1093\/ANNONC\/MDY156.","journal-title":"Ann Oncol"},{"key":"2253_CR6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/J.CLCC.2020.06.009","volume":"19","author":"F Tosi","year":"2020","unstructured":"Tosi F, Sartore-Bianchi A, Lonardi S, Amatu A, Leone F, Ghezzi S, et al. Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin Colorectal Cancer. 2020;19:256-262.e2. https:\/\/doi.org\/10.1016\/J.CLCC.2020.06.009.","journal-title":"Clin Colorectal Cancer"},{"key":"2253_CR7","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1634\/THEONCOLOGIST.2018-0785","volume":"24","author":"A Sartore-Bianchi","year":"2019","unstructured":"Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F, et al. Her2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist. 2019;24:1395\u2013402. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2018-0785.","journal-title":"Oncologist"},{"key":"2253_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/NRC1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341\u201354. https:\/\/doi.org\/10.1038\/NRC1609.","journal-title":"Nat Rev Cancer"},{"key":"2253_CR9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/PATH.4679","volume":"238","author":"SD Richman","year":"2016","unstructured":"Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238:562\u201370. https:\/\/doi.org\/10.1002\/PATH.4679.","journal-title":"J Pathol"},{"key":"2253_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/20565623.2025.2527482","author":"K Bartley","year":"2025","unstructured":"Bartley K, Snider J, Cho-Phan C, Wang J, Martin P, Simon C, et al. The prognostic impact of human epidermal growth factor receptor 2 status in metastatic colorectal cancer. Future Sci OA. 2025. https:\/\/doi.org\/10.1080\/20565623.2025.2527482.","journal-title":"Future Sci OA"},{"key":"2253_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/J.CLCC.2020.11.002","volume":"20","author":"M Yagisawa","year":"2021","unstructured":"Yagisawa M, Sawada K, Nakamura Y, Fujii S, Yuki S, Komatsu Y, et al. Prognostic value and molecular landscape of HER2 low-expressing metastatic colorectal cancer. Clin Colorectal Cancer. 2021;20:113-120.e1. https:\/\/doi.org\/10.1016\/J.CLCC.2020.11.002.","journal-title":"Clin Colorectal Cancer"},{"key":"2253_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01003","author":"MM Germani","year":"2025","unstructured":"Germani MM, Borelli B, Hashimoto T, Nakamura Y, Oldani S, Battaglin F, et al. Impact of human epidermal growth factor receptor 2 in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab or anti-EGFRs: exploratory analysis of eight randomized trials. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO-25-01003.","journal-title":"J Clin Oncol"},{"key":"2253_CR13","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1200\/JCO.23.01507","volume":"42","author":"F Battaglin","year":"2024","unstructured":"Battaglin F, Ou FS, Qu X, Hochster HS, Niedzwiecki D, Goldberg RM, et al. HER2 gene expression levels are predictive and prognostic in patients with metastatic colorectal cancer enrolled in CALGB\/SWOG 80405. J Clin Oncol. 2024;42:1890\u2013902. https:\/\/doi.org\/10.1200\/JCO.23.01507.","journal-title":"J Clin Oncol"},{"key":"2253_CR14","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1200\/JCO.24.00805\/ASSET\/79D4B87C-2CC3-482A-B255-ED179587814E\/ASSETS\/JCO.24.00805.FP.PNG","volume":"42","author":"A Sartore-Bianchi","year":"2024","unstructured":"Sartore-Bianchi A, Marsoni S, Amatu A, Torri V, Bonoldi E, Bardelli A, et al. How to test HER2 for predicting resistance to anti-epidermal growth factor receptor therapy in metastatic colorectal cancer? evidence from the secondary analysis of biomarkers of CALGB\/SWOG 80405. J Clin Oncol. 2024;42:3631\u20132. https:\/\/doi.org\/10.1200\/JCO.24.00805\/ASSET\/79D4B87C-2CC3-482A-B255-ED179587814E\/ASSETS\/JCO.24.00805.FP.PNG.","journal-title":"J Clin Oncol"},{"issue":"7572","key":"2253_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nature14969","volume":"526","author":"A Bertotti","year":"2015","unstructured":"Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526(7572):263\u20137. https:\/\/doi.org\/10.1038\/nature14969.","journal-title":"Nature"},{"key":"2253_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.3002442","volume":"3","author":"K Yonesaka","year":"2011","unstructured":"Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011;3:99ra86. https:\/\/doi.org\/10.1126\/SCITRANSLMED.3002442.","journal-title":"Sci Transl Med"},{"key":"2253_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","volume":"1","author":"A Bertotti","year":"2011","unstructured":"Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508\u201323. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0109.","journal-title":"Cancer Discov"},{"key":"2253_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00226","volume":"3","author":"K Raghav","year":"2019","unstructured":"Raghav K, Loree JM, Morris JS, Overman MJ, Yu R, Meric-Bernstam F, et al. Validation of HER2 amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis Oncol. 2019;3:1\u201313. https:\/\/doi.org\/10.1200\/PO.18.00226.","journal-title":"JCO Precis Oncol"},{"key":"2253_CR19","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1093\/ANNONC\/MDX546","volume":"28","author":"C Cremolini","year":"2017","unstructured":"Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case\u2013control study. Ann Oncol. 2017;28:3009\u201314. https:\/\/doi.org\/10.1093\/ANNONC\/MDX546.","journal-title":"Ann Oncol"},{"key":"2253_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104511","author":"D Ciardiello","year":"2025","unstructured":"Ciardiello D, Bielo LB, Napolitano S, Latiano TP, De Stefano A, Tamburini E, et al. Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial. ESMO Open. 2025. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104511.","journal-title":"ESMO Open"},{"key":"2253_CR21","doi-asserted-by":"crossref","unstructured":"Germani MM, et al. The prognostic and predictive role of HER2 amplification\/overexpression and HER2 mutations in metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab\/anti-EGFRs: An individual patient data pooled analysis of eight randomized trials. J Clin Oncol. 2025;43:3537.","DOI":"10.1200\/JCO.2025.43.16_suppl.3537"},{"key":"2253_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01710\/SUPPL_FILE\/PROTOCOL_JCO-24-01710.PDF","author":"KPS Raghav","year":"2025","unstructured":"Raghav KPS, Guthrie KA, Tan B, Denlinger CS, Fakih M, Overman MJ, et al. Trastuzumab plus pertuzumab versus cetuximab plus irinotecan in patients with RAS\/BRAF wild-type, HER2-positive, metastatic colorectal cancer (S1613): a randomized phase II trial. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO-24-01710\/SUPPL_FILE\/PROTOCOL_JCO-24-01710.PDF.","journal-title":"J Clin Oncol"},{"key":"2253_CR23","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","volume":"17","author":"A Sartore-Bianchi","year":"2016","unstructured":"Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)00150-9.","journal-title":"Lancet Oncol"},{"key":"2253_CR24","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/MODPATHOL.2015.98","volume":"28","author":"E Valtorta","year":"2015","unstructured":"Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28:1481\u201391. https:\/\/doi.org\/10.1038\/MODPATHOL.2015.98.","journal-title":"Mod Pathol"},{"key":"2253_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/J.CLCC.2018.05.006","volume":"17","author":"K Sawada","year":"2018","unstructured":"Sawada K, Nakamura Y, Yamanaka T, Kuboki Y, Yamaguchi D, Yuki S, et al. Prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17:198\u2013205. https:\/\/doi.org\/10.1016\/J.CLCC.2018.05.006.","journal-title":"Clin Colorectal Cancer"},{"key":"2253_CR26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/CAM4.228","volume":"3","author":"WS Lee","year":"2014","unstructured":"Lee WS, Park YH, Lee JN, Baek JH, Lee TH, Ha SY. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer Med. 2014;3:674. https:\/\/doi.org\/10.1002\/CAM4.228.","journal-title":"Cancer Med"},{"key":"2253_CR27","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/S00432-018-2744-Z","volume":"144","author":"L Shan","year":"2018","unstructured":"Shan L, Lv Y, Bai B, Huang X, Zhu H. Variability in HER2 expression between primary colorectal cancer and corresponding metastases. J Cancer Res Clin Oncol. 2018;144:2275\u201381. https:\/\/doi.org\/10.1007\/S00432-018-2744-Z.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2253_CR28","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/1535-7163.MCT-22-0630\/727379\/AM\/DISCORDANCE-OF-HER2-EXPRESSION-AND-OR","volume":"22","author":"TP DiPeri","year":"2023","unstructured":"DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, et al. Discordance of HER2 expression and\/or amplification on repeat testing. Mol Cancer Ther. 2023;22:976\u201384. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0630\/727379\/AM\/DISCORDANCE-OF-HER2-EXPRESSION-AND-OR.","journal-title":"Mol Cancer Ther"},{"key":"2253_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/S13000-024-01508-Y","volume":"19","author":"F D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo F, Monnien F, Overs A, Pem I, Dor F, Abad M, et al. Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer. Diagn Pathol. 2024;19:88. https:\/\/doi.org\/10.1186\/S13000-024-01508-Y.","journal-title":"Diagn Pathol"},{"issue":"4","key":"2253_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/03008916251345409","volume":"111","author":"D Lorenzini","year":"2025","unstructured":"Lorenzini D, Salvatori R, Volpi CC, Trupia DV, Niger M, Nichetti F, et al. Validating HER2 copy number variation assessment by NGS: a comparative analysis with immunohistochemistry and in situ hybridization. Tumori J. 2025;111(4):322\u201330. https:\/\/doi.org\/10.1177\/03008916251345409.","journal-title":"Tumori J"},{"key":"2253_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.HUMPATH.2017.02.004","volume":"66","author":"Y Shimada","year":"2017","unstructured":"Shimada Y, Yagi R, Kameyama H, Nagahashi M, Ichikawa H, Tajima Y, et al. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. Hum Pathol. 2017;66:1\u20139. https:\/\/doi.org\/10.1016\/J.HUMPATH.2017.02.004.","journal-title":"Hum Pathol"},{"key":"2253_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/AJCP\/AQZ031","volume":"152","author":"O Cenaj","year":"2019","unstructured":"Cenaj O, Ligon AH, Hornick JL, Sholl LM. Detection of ERBB2 amplification by next-generation sequencing predicts HER2 expression in colorectal carcinoma. Am J Clin Pathol. 2019;152:97\u2013108. https:\/\/doi.org\/10.1093\/AJCP\/AQZ031.","journal-title":"Am J Clin Pathol"},{"key":"2253_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1200\/PO.19.00154","volume":"4","author":"S Fujii","year":"2020","unstructured":"Fujii S, Magliocco AM, Kim J, Okamoto W, Kim JE, Sawada K, et al. International harmonization of provisional diagnostic criteria for ERBB2-amplified metastatic colorectal cancer allowing for screening by next-generation sequencing Panel. JCO Precis Oncol. 2020;4:6\u201319. https:\/\/doi.org\/10.1200\/PO.19.00154.","journal-title":"JCO Precis Oncol"},{"key":"2253_CR34","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1158\/1078-0432.CCR-18-3389","volume":"25","author":"G Siravegna","year":"2019","unstructured":"Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res. 2019;25:3046\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3389.","journal-title":"Clin Cancer Res"},{"key":"2253_CR35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/J.CCELL.2018.06.004","volume":"34","author":"G Siravegna","year":"2018","unstructured":"Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Cassingena A, et al. Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. Cancer Cell. 2018;34:148-162.e7. https:\/\/doi.org\/10.1016\/J.CCELL.2018.06.004.","journal-title":"Cancer Cell"},{"key":"2253_CR36","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/S41591-021-01553-W","volume":"27","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 2021;27:1899\u2013903. https:\/\/doi.org\/10.1038\/S41591-021-01553-W.","journal-title":"Nat Med"},{"key":"2253_CR37","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1200\/JCO.2023.41.16_SUPPL.3528","volume":"41","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Cercek A, Ng K, Siena S, Andre T, Van Cutsem E, et al. HER2 testing in the MOUNTAINEER trial: analysis of treatment response based on central HER2 assessment using IHC\/ISH and NGS. J Clin Oncol. 2023;41:3528\u20133528. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_SUPPL.3528.","journal-title":"J Clin Oncol"},{"key":"2253_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/J.CLCC.2024.02.001","volume":"23","author":"L Roazzi","year":"2024","unstructured":"Roazzi L, Patelli G, Bencardino KB, Amatu A, Bonazzina E, Tosi F, et al. Ongoing clinical trials and future research scenarios of circulating tumor DNA for the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2024;23:295\u2013308. https:\/\/doi.org\/10.1016\/J.CLCC.2024.02.001.","journal-title":"Clin Colorectal Cancer"},{"key":"2253_CR39","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","volume":"20","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20:518\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(18)30904-5.","journal-title":"Lancet Oncol"},{"key":"2253_CR40","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00306","author":"R Gupta","year":"2022","unstructured":"Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D\u2019Andre S, et al. Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: results from the TAPUR study. JCO Precis Oncol. 2022. https:\/\/doi.org\/10.1200\/PO.22.00306.","journal-title":"JCO Precis Oncol"},{"key":"2253_CR41","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.22.02636\/SUPPL_FILE\/PROTOCOL_JCO.22.02636.PDF","volume":"42","author":"CJ Sweeney","year":"2024","unstructured":"Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, et al. Mypathway human epidermal growth factor receptor 2 basket study: pertuzumab 1 trastuzumab treatment of a tissue-agnostic cohort of patients with human epidermal growth factor receptor 2\u2013altered advanced solid tumors. J Clin Oncol. 2024;42:258\u201365. https:\/\/doi.org\/10.1200\/JCO.22.02636\/SUPPL_FILE\/PROTOCOL_JCO.22.02636.PDF.","journal-title":"J Clin Oncol"},{"key":"2253_CR42","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.22.00022","author":"Y Narita","year":"2022","unstructured":"Narita Y, Yoshimoto T, Namai T, Asakawa T, Kawakami S, Gower-Page C, et al. Pertuzumab plus trastuzumab for treatment-refractory HER2-amplified metastatic colorectal cancer: comparison of the MyPathway trial with a real-world external control arm. JCO Clin Cancer Inform. 2022. https:\/\/doi.org\/10.1200\/CCI.22.00022.","journal-title":"JCO Clin Cancer Inform"},{"key":"2253_CR43","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","volume":"24","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Cercek A, Siena S, Andr\u00e9 T, Ng K, Van Cutsem E, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, ras wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24:496\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(23)00150-X.","journal-title":"Lancet Oncol"},{"key":"2253_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCA.2024.113988","volume":"202","author":"IAC Spiekman","year":"2024","unstructured":"Spiekman IAC, Zeverijn LJ, Geurts BS, Verkerk K, Mohammad SFH, van der Noort V, et al. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: results from the drug rediscovery protocol (DRUP). Eur J Cancer. 2024;202:113988. https:\/\/doi.org\/10.1016\/J.EJCA.2024.113988.","journal-title":"Eur J Cancer"},{"key":"2253_CR45","doi-asserted-by":"publisher","first-page":"S557","DOI":"10.1016\/j.annonc.2021.08.967","volume":"32","author":"A Amatu","year":"2021","unstructured":"Amatu A, Ghezzi S, Vaghi C, Mauri G, Bencardino K, Tosi F, et al. 446P bayesian monitoring of lapatinib (L) plus trastuzumab (T) treatment of HER2 positive metastatic colorectal cancer (MCRC): an observational cohort study. Ann Oncol. 2021;32:S557. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.967.","journal-title":"Ann Oncol"},{"key":"2253_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/ESMOOPEN-2020-000911","author":"A Sartore-Bianchi","year":"2020","unstructured":"Sartore-Bianchi A, Lonardi S, Martino C, Fenocchio E, Tosi F, Ghezzi S, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open. 2020. https:\/\/doi.org\/10.1136\/ESMOOPEN-2020-000911.","journal-title":"ESMO Open"},{"issue":"1","key":"2253_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-38032-4","volume":"14","author":"T Yoshino","year":"2023","unstructured":"Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al. Final Results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun. 2023;14(1):1\u201313. https:\/\/doi.org\/10.1038\/s41467-023-38032-4.","journal-title":"Nat Commun"},{"key":"2253_CR48","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","volume":"25","author":"K Raghav","year":"2024","unstructured":"Raghav K, Siena S, Takashima A, Kato T, Van den Eynde M, Pietrantonio F, et al. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25:1147\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(24)00380-2.","journal-title":"Lancet Oncol"},{"key":"2253_CR49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1200\/JCO.2022.40.4_SUPPL.119","volume":"40","author":"T Yoshino","year":"2022","unstructured":"Yoshino T, Bartolomeo MD, Raghav KPS, Masuishi T, Kawakami H, Yamaguchi K, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (Pts) with HER2-expressing metastatic colorectal cancer (MCRC): final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). J Clin Oncol. 2022;40:119\u2013119. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_SUPPL.119.","journal-title":"J Clin Oncol"},{"key":"2253_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/J.ESMOOP.2022.100404","author":"P Conte","year":"2022","unstructured":"Conte P, Ascierto PA, Patelli G, Danesi R, Vanzulli A, Sandomenico F, et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022. https:\/\/doi.org\/10.1016\/J.ESMOOP.2022.100404.","journal-title":"ESMO Open"},{"key":"2253_CR51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/J.CLCC.2022.07.003","volume":"21","author":"J Chang","year":"2022","unstructured":"Chang J, Xu M, Wang C, Huang D, Zhang Z, Chen Z, et al. Dual HER2 targeted therapy with pyrotinib and trastuzumab in refractory HER2 positive metastatic colorectal cancer: a result from HER2-FUSCC-G study. Clin Colorectal Cancer. 2022;21:347\u201353. https:\/\/doi.org\/10.1016\/J.CLCC.2022.07.003.","journal-title":"Clin Colorectal Cancer"},{"key":"2253_CR52","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/CAS.15660","volume":"114","author":"X Fu","year":"2023","unstructured":"Fu X, Ying J, Yang L, Fang W, Han W, Hu H, et al. Dual targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: a phase 2 trial. Cancer Sci. 2023;114:1067\u201374. https:\/\/doi.org\/10.1111\/CAS.15660.","journal-title":"Cancer Sci"},{"key":"2253_CR53","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/J.CLCC.2023.10.008","volume":"23","author":"H Zhou","year":"2024","unstructured":"Zhou H, Lv M, Li W, Wang Y, Wu J, Liu Q, et al. Efficacy of pyrotinib with\/without trastuzumab in treatment-refractory, HER2-positive metastatic colorectal cancer: result from a prospective observational study. Clin Colorectal Cancer. 2024;23:58\u201366. https:\/\/doi.org\/10.1016\/J.CLCC.2023.10.008.","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"2253_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-37029-3","volume":"14","author":"NE Weisser","year":"2023","unstructured":"Weisser NE, Sanches M, Escobar-Cabrera E, O\u2019Toole J, Whalen E, Chan PWY, et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023;14(1):1\u201322. https:\/\/doi.org\/10.1038\/s41467-023-37029-3.","journal-title":"Nat Commun"},{"key":"2253_CR55","doi-asserted-by":"publisher","first-page":"v167","DOI":"10.1093\/annonc\/mdz244.015","volume":"30","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam F, Hanna D, Beeram M, Lee K-W, Kang Y-K, Chaves J, et al. Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours. Ann Oncol. 2019;30:v167\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz244.015.","journal-title":"Ann Oncol"},{"key":"2253_CR56","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","volume":"23","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022;23:1558\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(22)00621-0.","journal-title":"Lancet Oncol"},{"key":"2253_CR57","doi-asserted-by":"publisher","first-page":"S436","DOI":"10.1016\/J.ANNONC.2024.08.585","volume":"35","author":"SY Rha","year":"2024","unstructured":"Rha SY, Lee K-W, Lee S, Kang Y-K, Chandana S, Escalante A, et al. 516MO Zanidatamab (Zani) + chemotherapy (CT) in first-line (1L) human epidermal growth factor receptor 2-positive (HER2+) advanced\/metastatic colorectal cancer (MCRC). Ann Oncol. 2024;35:S436\u20137. https:\/\/doi.org\/10.1016\/J.ANNONC.2024.08.585.","journal-title":"Ann Oncol"},{"key":"2253_CR58","doi-asserted-by":"publisher","first-page":"S478","DOI":"10.1016\/j.annonc.2023.09.1870","volume":"34","author":"J Li","year":"2023","unstructured":"Li J, Luo S, Liu T, Dong L, Yuan X, Feng J, et al. 684p phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC). Ann Oncol. 2023;34:S478. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1870.","journal-title":"Ann Oncol"},{"key":"2253_CR59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02044","author":"H Yao","year":"2024","unstructured":"Yao H, Yan M, Tong Z, Wu X, Ryu M-H, Park JJ, et al. Safety, efficacy, and pharmacokinetics of SHR-A1811, a human epidermal growth factor receptor 2\u2013directed antibody-drug conjugate, in human epidermal growth factor receptor 2\u2013expressing or mutated advanced solid tumors: a global phase I trial. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.23.02044.","journal-title":"J Clin Oncol"},{"key":"2253_CR60","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/J.EJCA.2022.04.019","volume":"170","author":"D Rossini","year":"2022","unstructured":"Rossini D, Germani MM, Lonardi S, Pietrantonio F, Dell\u2019Aquila E, Borelli B, et al. Treatments after second progression in metastatic colorectal cancer: a pooled analysis of the TRIBE and TRIBE2 studies. Eur J Cancer. 2022;170:64\u201372. https:\/\/doi.org\/10.1016\/J.EJCA.2022.04.019.","journal-title":"Eur J Cancer"},{"key":"2253_CR61","doi-asserted-by":"publisher","first-page":"S411","DOI":"10.1016\/J.ANNONC.2023.09.1742","volume":"34","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Cercek A, Ng K, Siena S, Andr\u00e9 T, Van Cutsem E, et al. 551o impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (MCRC) in MOUNTAINEER. Ann Oncol. 2023;34:S411\u20132. https:\/\/doi.org\/10.1016\/J.ANNONC.2023.09.1742.","journal-title":"Ann Oncol"},{"key":"2253_CR62","doi-asserted-by":"publisher","first-page":"626","DOI":"10.4143\/CRT.2022.1058","volume":"55","author":"T Xu","year":"2023","unstructured":"Xu T, Wang X, Xin Y, Wang Z, Gong J, Zhang X, et al. Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: a phase ii single-arm study and exploratory biomarker analysis. Cancer Res Treat. 2023;55:626\u201335. https:\/\/doi.org\/10.4143\/CRT.2022.1058.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"2253_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-53223-3","volume":"15","author":"S Siena","year":"2024","unstructured":"Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, et al. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024;15(1):1\u201312. https:\/\/doi.org\/10.1038\/s41467-024-53223-3.","journal-title":"Nat Commun"},{"key":"2253_CR64","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/1078-0432.CCR-23-1379","volume":"30","author":"G Randon","year":"2024","unstructured":"Randon G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E, et al. Negative hyperselection of patients with HER2+ and RAS wild-type metastatic colorectal cancer receiving dual HER2 blockade: the PRESSING-HER2 study. Clin Cancer Res. 2024;30:436\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1379.","journal-title":"Clin Cancer Res"},{"key":"2253_CR65","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00385","author":"M Imai","year":"2025","unstructured":"Imai M, Nakamura Y, Shin S, Okamoto W, Kato T, Esaki T, et al. Artificial intelligence-powered human epidermal growth factor receptor 2 and tumor microenvironment analysis in human epidermal growth factor receptor 2-amplified metastatic colorectal cancer: exploratory analysis of phase II TRIUMPH trial. JCO Precis Oncol. 2025. https:\/\/doi.org\/10.1200\/PO-24-00385.","journal-title":"JCO Precis Oncol"},{"key":"2253_CR66","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1158\/1078-0432.CCR-18-3440\/74915\/AM\/PATIENT-DERIVED-XENOGRAFTS-AND-MATCHED-CELL-LINES","volume":"25","author":"L Lazzari","year":"2019","unstructured":"Lazzari L, Corti G, Picco G, Isella C, Montone M, Arcela P, et al. Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer. Clin Cancer Res. 2019;25:6243\u201359. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3440\/74915\/AM\/PATIENT-DERIVED-XENOGRAFTS-AND-MATCHED-CELL-LINES.","journal-title":"Clin Cancer Res"},{"key":"2253_CR67","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1200\/JCO.2025.43.4_SUPPL.277","volume":"43","author":"C Hoyek","year":"2025","unstructured":"Hoyek C, Zheng-Lin B, Pirozzi A, Abidoye O, Eslinger C, Iida N, et al. Acquired gene alterations potentially related to resistance to anti-HER2 therapy in HER2-positive metastatic colorectal cancer (MCRC). J Clin Oncol. 2025;43:277\u2013277. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_SUPPL.277.","journal-title":"J Clin Oncol"},{"key":"2253_CR68","doi-asserted-by":"publisher","first-page":"S705","DOI":"10.1016\/j.annonc.2022.07.508","volume":"33","author":"A Sartore Bianchi","year":"2022","unstructured":"Sartore Bianchi A, Lonardi S, Amatu A, Bergamo F, Mauri G, Martino C, et al. 370p trastuzumab-emtansine (T-DM1) in HER2-amplified metastatic colorectal cancer patients progressing to trastuzumab-lapatinib: the HERACLES RESCUE phase II trial. Ann Oncol. 2022;33:S705\u20136. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.508.","journal-title":"Ann Oncol"},{"key":"2253_CR69","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/J.ANNONC.2025.05.056","volume":"36","author":"AS Bianchi","year":"2025","unstructured":"Bianchi AS, Mauri G, Troiani T, Bergamo F, Gori V, Ghezzi S, et al. 44P rechallenge with anti-HER2 regimens in metastatic colorectal cancer: the retrospective RHEA study. Ann Oncol. 2025;36:S27. https:\/\/doi.org\/10.1016\/J.ANNONC.2025.05.056.","journal-title":"Ann Oncol"},{"key":"2253_CR70","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/esmoopen-2017-000299","volume":"3","author":"E Martinelli","year":"2018","unstructured":"Martinelli E, Troiani T, Sforza V, Martini G, Cardone C, Vitiello PP, et al. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open. 2018;3:299. https:\/\/doi.org\/10.1136\/esmoopen-2017-000299.","journal-title":"ESMO Open"},{"key":"2253_CR71","doi-asserted-by":"publisher","first-page":"1481326","DOI":"10.3389\/FIMMU.2024.1481326","volume":"15","author":"N Song","year":"2024","unstructured":"Song N, Teng Y, Shi J, Teng Z, Jin B, Qu J, et al. A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia\/Ib first-in-human, open-label, single center study. Front Immunol. 2024;15:1481326. https:\/\/doi.org\/10.3389\/FIMMU.2024.1481326.","journal-title":"Front Immunol"},{"key":"2253_CR72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_SUPPL.TPS261","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab TS, Cutsem EV, Tabernero J, Siena S, Yoshino T, Nakamura Y, et al. Mountaineer-03: phase 3 study of tucatinib, trastuzumab, and MFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer\u2014trial in progress. J Clin Oncol. 2023;41:TPS261\u2013TPS261. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_SUPPL.TPS261.","journal-title":"J Clin Oncol"},{"key":"2253_CR73","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0306","author":"B Wilding","year":"2025","unstructured":"Wilding B, Woelflingseder L, Baum A, Chylinski K, Vainorius G, Gibson N, et al. Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers. Cancer Discov. 2025. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0306.","journal-title":"Cancer Discov"},{"key":"2253_CR74","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1200\/JCO-24-01727","volume":"43","author":"JV Heymach","year":"2025","unstructured":"Heymach JV, Opdam F, Barve M, Tu HY, Wu YL, Berz D, et al. HER2-selective tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with advanced\/metastatic solid tumors with HER2 alterations: a phase Ia dose-escalation study. J Clin Oncol. 2025;43:1337. https:\/\/doi.org\/10.1200\/JCO-24-01727.","journal-title":"J Clin Oncol"},{"key":"2253_CR75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.TPS3187","author":"AM Schram","year":"2025","unstructured":"Schram AM, Clay TD, Prenen H, Park JJ, Lunger L, Hussain J, et al. Beamion PANTUMOR-1: a phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2 -mutated or overexpressed\/amplified solid tumors. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_SUPPL.TPS3187.","journal-title":"J Clin Oncol"},{"key":"2253_CR76","doi-asserted-by":"publisher","first-page":"S749","DOI":"10.1016\/J.ANNONC.2022.07.589","volume":"33","author":"K Jhaveri","year":"2022","unstructured":"Jhaveri K, Han H, Dotan E, Oh D-Y, Ferrario C, Tolcher A, et al. 460MO preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers. Ann Oncol. 2022;33:S749\u201350. https:\/\/doi.org\/10.1016\/J.ANNONC.2022.07.589.","journal-title":"Ann Oncol"},{"key":"2253_CR77","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-23-B130","volume":"22","author":"D-Y Oh","year":"2023","unstructured":"Oh D-Y, Bedard PL, Lee K-W, Han HS, Kang Y-K, Miller WH, et al. Abstract B130: phase 1 study of zanidatamab zovodotin (ZW49): safety profile and recommended dose (RD) in patients with human epidermal growth factor 2 (HER2)-positive solid cancers. Mol Cancer Ther. 2023;22:B130\u2013B130. https:\/\/doi.org\/10.1158\/1535-7163.TARG-23-B130.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2253_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-45996-4","volume":"15","author":"EL Hardaker","year":"2024","unstructured":"Hardaker EL, Sanseviero E, Karmokar A, Taylor D, Milo M, Michaloglou C, et al. The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nat Commun. 2024;15(1):1\u201320. https:\/\/doi.org\/10.1038\/s41467-024-45996-4.","journal-title":"Nat Commun"},{"key":"2253_CR79","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/S10120-021-01168-7\/TABLES\/4","volume":"24","author":"Y Xu","year":"2021","unstructured":"Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody\u2013MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021;24:913\u201325. https:\/\/doi.org\/10.1007\/S10120-021-01168-7\/TABLES\/4.","journal-title":"Gastric Cancer"},{"key":"2253_CR80","doi-asserted-by":"publisher","first-page":"e15003","DOI":"10.1200\/JCO.2024.42.16_SUPPL.E15003","volume":"42","author":"H Xu","year":"2024","unstructured":"Xu H, Peng J, Wu H, Yang L, Wang W, Wang Y, et al. Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation\/amplified metastatic colorectal cancer refractory to at least two standard regimens: a prospective, exploratory, single-arm study. J Clin Oncol. 2024;42:e15003\u2013e15003. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_SUPPL.E15003.","journal-title":"J Clin Oncol"},{"key":"2253_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102415","volume":"68","author":"Y Wang","year":"2024","unstructured":"Wang Y, Gong J, Wang A, Wei J, Peng Z, Wang X, et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine. 2024;68:102415. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102415.","journal-title":"EClinicalMedicine"},{"issue":"3","key":"2253_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-024-06572-2","volume":"15","author":"H Liu","year":"2024","unstructured":"Liu H, Zhou D, Liu D, Xu X, Zhang K, Hu R, et al. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer. Cell Death Dis. 2024;15(3):1\u201313. https:\/\/doi.org\/10.1038\/s41419-024-06572-2.","journal-title":"Cell Death Dis"},{"key":"2253_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2025.1431422","author":"J Chen","year":"2025","unstructured":"Chen J, Wang J, Zheng Q. Disitamab vedotin combined with pyrotinib as salvage treatment in Her-2-amplified treatment refractory metastatic colorectal cancer: a case report. Front Pharmacol. 2025. https:\/\/doi.org\/10.3389\/FPHAR.2025.1431422.","journal-title":"Front Pharmacol"},{"key":"2253_CR84","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.1073\/PNAS.1016569108","volume":"108","author":"J Stagg","year":"2011","unstructured":"Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 MAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 MAb therapy. Proc Natl Acad Sci USA. 2011;108:7142\u20137. https:\/\/doi.org\/10.1073\/PNAS.1016569108.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2253_CR85","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41556-019-0352-z","volume":"21","author":"S Wu","year":"2019","unstructured":"Wu S, Zhang Q, Zhang F, Meng F, Liu S, Zhou R, et al. HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nat Cell Biol. 2019;21(8):1027\u201340. https:\/\/doi.org\/10.1038\/s41556-019-0352-z.","journal-title":"Nat Cell Biol"},{"key":"2253_CR86","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1158\/0008-5472.CAN-16-2774\/652776\/AM\/TRASTUZUMAB-INCREASES-HER2-UPTAKE-AND-CROSS","volume":"77","author":"VA Gall","year":"2017","unstructured":"Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, et al. Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells. Cancer Res. 2017;77:5374\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2774\/652776\/AM\/TRASTUZUMAB-INCREASES-HER2-UPTAKE-AND-CROSS.","journal-title":"Cancer Res"},{"key":"2253_CR87","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197\u2013208. https:\/\/doi.org\/10.1016\/S0140-6736(23)02033-0.","journal-title":"Lancet"},{"key":"2253_CR88","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1056\/NEJMC2408121","volume":"391","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab in HER2-positive gastric cancer. N Engl J Med. 2024;391:1360\u20132. https:\/\/doi.org\/10.1056\/NEJMC2408121.","journal-title":"N Engl J Med"},{"issue":"23","key":"2253_CR89","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMOA2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, Met \u00d6, Kessels R, Geukes Foppen MH, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387(23):2113\u201325. https:\/\/doi.org\/10.1056\/NEJMOA2210233.","journal-title":"N Engl J Med"},{"key":"2253_CR90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0880","author":"L Hu","year":"2025","unstructured":"Hu L, Fan C, Bross P, Das A, Cho ES, Knudson KM, et al. FDA approval summary: lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1-based immunotherapy. Clin Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0880.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2253_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-04100-0","volume":"12","author":"J Xu","year":"2021","unstructured":"Xu J, Meng Q, Sun H, Zhang X, Yun J, Li B, et al. HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer. Cell Death Dis. 2021;12(12):1\u201311. https:\/\/doi.org\/10.1038\/s41419-021-04100-0.","journal-title":"Cell Death Dis"},{"key":"2253_CR92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_SUPPL.TPS2679","volume":"42","author":"S Makawita","year":"2024","unstructured":"Makawita S, Gibbs JM, McFadden DR, Porter C, Shaw AR, Robertson C, et al. Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST for treatment of advanced HER2-positive solid tumors (VISTA). J Clin Oncol. 2024;42:TPS2679\u2013TPS2679. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_SUPPL.TPS2679.","journal-title":"J Clin Oncol"},{"key":"2253_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z","author":"KA Reiss","year":"2025","unstructured":"Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03495-z.","journal-title":"Nat Med"},{"key":"2253_CR94","doi-asserted-by":"publisher","unstructured":"Mishima Y, Isoda F, Matsumoto N, Hiranuka K, Yamada T, Fujinami N, Shimomura M, Suzuki T, Nakatsura T, Nakamura N, et al. 1006P ACE1702, a first-in-class, off-the-shelf, selected natural killer cell [ONK] product using antibody cell conjugation technology [ACC], with pre-clinical and early clinical activity in HER2 < 3+ tumors. 2021. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1389.","DOI":"10.1016\/j.annonc.2021.08.1389"},{"key":"2253_CR95","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1158\/2326-6066.CIR-21-0722","volume":"10","author":"F Janku","year":"2022","unstructured":"Janku F, Han SW, Doi T, Amatu A, Ajani JA, Kuboki Y, et al. Preclinical characterization and phase I study of an anti-HER2-TLR7 immune-stimulator antibody conjugate in patients with HER2+ malignancies. Cancer Immunol Res. 2022;10:1441\u201361. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0722.","journal-title":"Cancer Immunol Res"},{"key":"2253_CR96","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO.2023.41.16_SUPPL.2538","volume":"41","author":"BT Li","year":"2023","unstructured":"Li BT, Pegram MD, Lee K-W, Sharma M, Lee J, Spira AI, et al. A phase 1\/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors. J Clin Oncol. 2023;41:2538\u20132538. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_SUPPL.2538.","journal-title":"J Clin Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02253-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02253-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02253-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T02:19:28Z","timestamp":1775701168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02253-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2253"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02253-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SS is scientific advisory board member for Amgen, Bayer, Bristol-Myers Squibb, CheckmAb, Clovis, Daiichi-Sankyo, Istituto Nazionale Genetica Medica, Merck, Ospedale San Raffaele, Roche-Genentech, and Seattle Genetics. AS-B is an advisory board member for Amgen, Bayer, Novartis, Pierre-Fabre, and Takeda. KB is an advisory board member for AstraZeneca. AA is an advisory board member for Amgen, Italfarmaco, Merck Serono. JR reports personal speaker honoraria from Sanofi, Pfizer, Takeda, BMS, Merck and Amgen; and accommodation expenses from Pierre Fabre, Servier, Amgen, and Merck. EE reports the following potential conflicts of interest: Honoraria, Consulting or Advisory Role, and Speakers's Bureau: Agenus, Amgen, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Cure Teq AG, GlaxoSmithKline, Hoffman La \u2013 Roche, Janssen, Johnson&Johnson, Lilly, Medscape, Merck Serono, MSD, Nordic Group BV, Novartis, Organon, Pfizer, Pierre Fabre, Repare Therapeutics Inc., RIN Institute Inc., Rottapharm Biotech, Sanofi, Seagen International GmbH, Servier, and Takeda. CV; FT; GM; EB; DP; LL; FV; MM; LM; AB; GM; SG; and GP declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"CV: conceptualization, methodology, investigation, data curation, writing \u2013 original draft, visualization; FT: writing \u2013 review & editing; GM: conceptualization, methodology, writing \u2013 review & editing; EB: writing \u2013 review & editing; AA: writing \u2013 review & editing; KB: writing \u2013 review & editing; DP: writing \u2013 review & editing; LL: writing \u2013 review & editing; FV: writing \u2013 review & editing; MM: writing \u2013 review & editing; LM: writing \u2013 review & editing; AB: writing \u2013 review & editing; GM: writing \u2013 review & editing; SG: writing \u2013 review & editing; GP: writing \u2013 review & editing; JR: data curation, validation, writing \u2013 review & editing; EE: validation, writing \u2013 review & editing; ASB: conceptualization, methodology, data curation, validation, writing \u2013 review & editing, supervision; SS.: conceptualization, methodology, validation, writing \u2013 review & editing, supervision.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}